Clinical AdvisorAACE Updates Guidance on Obesity, Adiposity-Based Chronic Disease

✅ Guideline Update

The AACE updated its obesity guidelines to center treatment on adiposity-based chronic disease (ABCD), a framework encompassing risk factors, preclinical obesity, and obesity-related complications (ORCD). Three severity stages guide treatment intensity, with stage 3 (severe ORCD) favoring second-generation agents targeting at least 15% weight reduction.

Clinical Considerations

• Semaglutide is the only obesity medication with a cardiovascular outcomes trial supporting MACE reduction; preferred for chronic kidney disease and osteoarthritis
• Tirzepatide or semaglutide are first-tier for type 2 diabetes, MASH, HFpEF, and blood pressure lowering; tirzepatide preferred for obstructive sleep apnea
• Early response assessment at 3 months: less than 5% weight loss warrants strategy change — intensify lifestyle therapy, switch agents, or combine
• Compounded semaglutide and tirzepatide alternatives are explicitly discouraged; safety, efficacy, and quality unverified
• BMI alone is insufficient; waist circumference and waist-to-height ratio are required for cardiometabolic risk assessment

Practice Applications

• Consider step therapy: initiate first-generation agents for stages 1 and 2; reserve second-generation agents for stage 3
• Recognize that optimal dosing may fall below the maximally approved dose when balancing efficacy and tolerability
• Integrate complication-specific drug selection using ORCD type, comorbidities, contraindications, and cost
• Monitor for GLP-1 GI side effects during titration; begin at lowest dose and titrate slowly
• Screen all patients for anxiety, depression, eating disorders, and internalized weight bias as part of the treatment plan